Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9202272 | 0.89 | LMNA (0.44) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL1802571 | 0.80 | HSD17B10 (0.42) | KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL1803803 | 0.78 | KDM4E (0.40) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL38953 | 0.78 | SMN1; SMN2 (0.56) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL1806745 | 0.77 | HSD17B10 (0.37) | SMN1; SMN2NPSR1ALDH1A1 | |
| Water SCHEMBL7733637 | 0.76 | SMN1; SMN2 (0.54) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL29829697 | 0.76 | SMN1; SMN2 (0.54) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| Water SCHEMBL4837114 | 0.76 | SMN1; SMN2 (0.54) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL20704047 | 0.76 | SMN1; SMN2 (0.54) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| Iodide SCHEMBL11830139 | 0.76 | SMN1; SMN2 (0.54) | KDM4ELMNACYP2C19SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-08-12 | — | — | US | disclosed |
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2020-11-26 | — | — | US | disclosed |
| US-7402639-B2 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-07-22 | — | — | US | disclosed |
| US-6927295-B2 | A polymerization catalyst for free radical polymerization of ethylenically unsaturated monomers | CIBA SPECIALTY CHEMICALS CORP. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20050131177-A1 | 1-Alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (SE) | 2005-06-16 | — | — | US | disclosed |
| US-6683142-B2 | PROVIDE POLYMERIC RESIN PRODUCTS HAVING LOW POLYDISPERSITY. | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030220423-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (CH) | 2003-11-27 | — | — | US | disclosed |
| US-20020107397-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6353107-B1 | FREE RADICAL CATALYSTS FOR ADDITION POLYMERIZATION; NARROW MOLECULAR WEIGHT DISTRIBUTION; HIGH PURITY AND COLORLESS | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131177-A1 | 1-Alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | PYM1, PTGER1, CBR1 | KDM4E 1318/4885LMNA 213/4885CYP2C19 1143/4885 |
| US-20020107397-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | CBR1, PYM1, ELOC | KDM4E 2651/4885LMNA 156/4885CYP2C19 1389/4885 |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | KDM4E 4286/4885LMNA 3683/4885CYP2C19 3157/4885 |
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | MTAP, PRMT5, TET3 | KDM4E 142/4885LMNA 1837/4885CYP2C19 1241/4885 |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | KDM4E 4464/4885LMNA 3445/4885CYP2C19 4040/4885 |
| US-20030220423-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | PYM1, ELOC, CBR1 | KDM4E 2507/4885LMNA 147/4885CYP2C19 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.